ID   PLPL3_HUMAN             Reviewed;         481 AA.
AC   Q9NST1; B0QYI0; B2RCL3; B3KW00; Q6P1A1; Q96CB4;
DT   03-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 2.
DT   10-MAY-2017, entry version 135.
DE   RecName: Full=Patatin-like phospholipase domain-containing protein 3;
DE            EC=3.1.1.3;
DE   AltName: Full=Acylglycerol O-acyltransferase;
DE            EC=2.3.1.-;
DE   AltName: Full=Adiponutrin;
DE   AltName: Full=Calcium-independent phospholipase A2-epsilon;
DE            Short=iPLA2-epsilon;
GN   Name=PNPLA3; Synonyms=ADPN, C22orf20;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12529303; DOI=10.1101/gr.695703;
RA   Collins J.E., Goward M.E., Cole C.G., Smink L.J., Huckle E.J.,
RA   Knowles S., Bye J.M., Beare D.M., Dunham I.;
RT   "Reevaluating human gene annotation: a second-generation analysis of
RT   chromosome 22.";
RL   Genome Res. 13:27-36(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   GLU-434.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS CYS-115; MET-148 AND GLU-434.
RC   TISSUE=Brain, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-434.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   GLY-99; MET-148 AND GLU-434.
RC   TISSUE=Brain, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15364929; DOI=10.1074/jbc.M407841200;
RA   Jenkins C.M., Mancuso D.J., Yan W., Sims H.F., Gibson B., Gross R.W.;
RT   "Identification, cloning, expression, and purification of three novel
RT   human calcium-independent phospholipase A2 family members possessing
RT   triacylglycerol lipase and acylglycerol transacylase activities.";
RL   J. Biol. Chem. 279:48968-48975(2004).
RN   [8]
RP   INDUCTION.
RX   PubMed=15181042; DOI=10.1210/jc.2003-031978;
RA   Liu Y.-M., Moldes M., Bastard J.-P., Bruckert E., Viguerie N.,
RA   Hainque B., Basdevant A., Langin D., Pairault J., Clement K.;
RT   "Adiponutrin: A new gene regulated by energy balance in human adipose
RT   tissue.";
RL   J. Clin. Endocrinol. Metab. 89:2684-2689(2004).
RN   [9]
RP   VARIANT MET-148, AND POLYMORPHISM.
RX   PubMed=18728122; DOI=10.1530/EJE-08-0426;
RA   Johansson L.E., Lindblad U., Larsson C.A., Raastam L.,
RA   Ridderstraale M.;
RT   "Polymorphisms in the adiponutrin gene are associated with increased
RT   insulin secretion and obesity.";
RL   Eur. J. Endocrinol. 159:577-583(2008).
RN   [10]
RP   VARIANTS MET-148 AND ILE-453, AND INVOLVEMENT IN SUSCEPTIBILITY TO
RP   NAFLD1.
RX   PubMed=18820647; DOI=10.1038/ng.257;
RA   Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D.,
RA   Pennacchio L.A., Boerwinkle E., Cohen J.C., Hobbs H.H.;
RT   "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic
RT   fatty liver disease.";
RL   Nat. Genet. 40:1461-1465(2008).
RN   [11]
RP   VARIANT MET-148, AND INVOLVEMENT IN SUSCEPTIBILITY TO NAFLD1.
RX   PubMed=19224197; DOI=10.1007/s00125-009-1285-z;
RA   Kotronen A., Johansson L.E., Johansson L.M., Roos C., Westerbacka J.,
RA   Hamsten A., Bergholm R., Arkkila P., Arola J., Kiviluoto T.,
RA   Fisher R.M., Ehrenborg E., Orho-Melander M., Ridderstrale M.,
RA   Groop L., Yki-Jarvinen H.;
RT   "A common variant in PNPLA3, which encodes adiponutrin, is associated
RT   with liver fat content in humans.";
RL   Diabetologia 52:1056-1060(2009).
RN   [12]
RP   CHARACTERIZATION OF VARIANT MET-148.
RX   PubMed=20034933; DOI=10.1074/jbc.M109.064501;
RA   He S., McPhaul C., Li J.Z., Garuti R., Kinch L., Grishin N.V.,
RA   Cohen J.C., Hobbs H.H.;
RT   "A sequence variation (I148M) in PNPLA3 associated with nonalcoholic
RT   fatty liver disease disrupts triglyceride hydrolysis.";
RL   J. Biol. Chem. 285:6706-6715(2010).
RN   [13]
RP   VARIANT MET-148, AND INVOLVEMENT IN SUSCEPTIBILITY TO NAFLD1.
RX   PubMed=19738004; DOI=10.1194/jlr.P900013-JLR200;
RA   Sookoian S., Castano G.O., Burgueno A.L., Gianotti T.F.,
RA   Rosselli M.S., Pirola C.J.;
RT   "A nonsynonymous gene variant in the adiponutrin gene is associated
RT   with nonalcoholic fatty liver disease severity.";
RL   J. Lipid Res. 50:2111-2116(2009).
RN   [14]
RP   VARIANTS NAFLD1 THR-76; VAL-104 AND MET-200.
RX   PubMed=27288299; DOI=10.1016/j.clinre.2016.05.004;
RA   Zegers D., Verrijken A., Francque S., de Freitas F., Beckers S.,
RA   Aerts E., Ruppert M., Hubens G., Michielsen P., Van Hul W.,
RA   Van Gaal L.F.;
RT   "Screening for rare variants in the PNPLA3 gene in obese liver biopsy
RT   patients.";
RL   Clin. Res. Hepatol. Gastroenterol. 40:715-721(2016).
CC   -!- FUNCTION: Multifunctional enzyme which has both triacylglycerol
CC       lipase and acylglycerol O-acyltransferase activities.
CC       {ECO:0000269|PubMed:15364929}.
CC   -!- CATALYTIC ACTIVITY: Triacylglycerol + H(2)O = diacylglycerol + a
CC       carboxylate.
CC   -!- PATHWAY: Glycerolipid metabolism; triacylglycerol degradation.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:15364929};
CC       Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:15364929}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NST1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NST1-2; Sequence=VSP_036222;
CC         Note=No experimental confirmation available.;
CC   -!- INDUCTION: By changes in energy balance: down-regulated following
CC       very low-calorie diet, whereas refeeding elevates the mRNA level.
CC       {ECO:0000269|PubMed:15181042}.
CC   -!- POLYMORPHISM: Polymorphic variation at position 148 influences
CC       insulin secretion levels and obesity. In obese subjects the body
CC       mass index and waist are higher in carriers of the Ile-148 allele.
CC       The Ile-148 carriers also display decreased insulin secretion in
CC       response to oral glucose tolerance test. Met-148 allele carriers
CC       are seemingly more insulin resistant at a lower body mass index.
CC       {ECO:0000269|PubMed:18728122}.
CC   -!- DISEASE: Non-alcoholic fatty liver disease 1 (NAFLD1)
CC       [MIM:613282]: A condition characterized by accumulation of
CC       triglycerides in the liver. It is associated with adverse
CC       metabolic consequences, including insulin resistance and
CC       dyslipidemia. In a subset of individuals, hepatic steatosis
CC       promotes an inflammatory response in the liver, referred to as
CC       steatohepatitis, which can progress to cirrhosis and liver cancer.
CC       NAFLD is the most common form of liver disease in Western
CC       countries. {ECO:0000269|PubMed:18820647,
CC       ECO:0000269|PubMed:19224197, ECO:0000269|PubMed:19738004,
CC       ECO:0000269|PubMed:27288299}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL138578; CAB71238.2; -; mRNA.
DR   EMBL; CR456476; CAG30362.1; -; mRNA.
DR   EMBL; AK123806; BAG53962.1; -; mRNA.
DR   EMBL; AK315166; BAG37610.1; -; mRNA.
DR   EMBL; AL023654; CAI21791.1; -; Genomic_DNA.
DR   EMBL; AL035398; CAI21791.1; JOINED; Genomic_DNA.
DR   EMBL; AL035398; CAI22840.1; -; Genomic_DNA.
DR   EMBL; AL023654; CAI22840.1; JOINED; Genomic_DNA.
DR   EMBL; AL023654; CAQ07959.1; -; Genomic_DNA.
DR   EMBL; AL035398; CAQ07959.1; JOINED; Genomic_DNA.
DR   EMBL; AL035398; CAQ09484.1; -; Genomic_DNA.
DR   EMBL; AL023654; CAQ09484.1; JOINED; Genomic_DNA.
DR   EMBL; CH471138; EAW73324.1; -; Genomic_DNA.
DR   EMBL; BC014449; AAH14449.2; -; mRNA.
DR   EMBL; BC065195; AAH65195.1; -; mRNA.
DR   CCDS; CCDS14054.1; -. [Q9NST1-1]
DR   RefSeq; NP_079501.2; NM_025225.2. [Q9NST1-1]
DR   UniGene; Hs.654800; -.
DR   ProteinModelPortal; Q9NST1; -.
DR   BioGrid; 123247; 4.
DR   IntAct; Q9NST1; 2.
DR   STRING; 9606.ENSP00000216180; -.
DR   SwissLipids; SLP:000000282; -.
DR   iPTMnet; Q9NST1; -.
DR   PhosphoSitePlus; Q9NST1; -.
DR   BioMuta; PNPLA3; -.
DR   DMDM; 32469599; -.
DR   MaxQB; Q9NST1; -.
DR   PaxDb; Q9NST1; -.
DR   PeptideAtlas; Q9NST1; -.
DR   PRIDE; Q9NST1; -.
DR   DNASU; 80339; -.
DR   Ensembl; ENST00000216180; ENSP00000216180; ENSG00000100344. [Q9NST1-1]
DR   Ensembl; ENST00000423180; ENSP00000397987; ENSG00000100344. [Q9NST1-2]
DR   GeneID; 80339; -.
DR   KEGG; hsa:80339; -.
DR   UCSC; uc003bei.1; human. [Q9NST1-1]
DR   CTD; 80339; -.
DR   DisGeNET; 80339; -.
DR   GeneCards; PNPLA3; -.
DR   H-InvDB; HIX0159175; -.
DR   HGNC; HGNC:18590; PNPLA3.
DR   HPA; HPA058058; -.
DR   MalaCards; PNPLA3; -.
DR   MIM; 609567; gene.
DR   MIM; 613282; phenotype.
DR   neXtProt; NX_Q9NST1; -.
DR   OpenTargets; ENSG00000100344; -.
DR   Orphanet; 33271; Non-alcoholic fatty liver disease.
DR   PharmGKB; PA38592; -.
DR   eggNOG; KOG3773; Eukaryota.
DR   eggNOG; ENOG410XSQS; LUCA.
DR   GeneTree; ENSGT00390000005295; -.
DR   HOGENOM; HOG000007467; -.
DR   HOVERGEN; HBG007046; -.
DR   InParanoid; Q9NST1; -.
DR   KO; K13534; -.
DR   OMA; FDAKTTI; -.
DR   OrthoDB; EOG091G05MG; -.
DR   PhylomeDB; Q9NST1; -.
DR   TreeFam; TF314272; -.
DR   Reactome; R-HSA-1482883; Acyl chain remodeling of DAG and TAG.
DR   UniPathway; UPA00256; -.
DR   GeneWiki; PNPLA3; -.
DR   GenomeRNAi; 80339; -.
DR   PRO; PR:Q9NST1; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000100344; -.
DR   CleanEx; HS_PNPLA3; -.
DR   ExpressionAtlas; Q9NST1; baseline and differential.
DR   Genevisible; Q9NST1; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005811; C:lipid particle; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0016411; F:acylglycerol O-acyltransferase activity; TAS:Reactome.
DR   GO; GO:0051265; F:diolein transacylation activity; IDA:UniProtKB.
DR   GO; GO:0004465; F:lipoprotein lipase activity; TAS:Reactome.
DR   GO; GO:0051264; F:mono-olein transacylation activity; IDA:UniProtKB.
DR   GO; GO:0004623; F:phospholipase A2 activity; IDA:UniProtKB.
DR   GO; GO:0004806; F:triglyceride lipase activity; IDA:UniProtKB.
DR   GO; GO:0036155; P:acylglycerol acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0055088; P:lipid homeostasis; IBA:GO_Central.
DR   GO; GO:0036153; P:triglyceride acyl-chain remodeling; IDA:CACAO.
DR   GO; GO:0019432; P:triglyceride biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0019433; P:triglyceride catabolic process; IDA:UniProtKB.
DR   InterPro; IPR016035; Acyl_Trfase/lysoPLipase.
DR   InterPro; IPR033562; PLPL.
DR   InterPro; IPR002641; PNPLA_dom.
DR   PANTHER; PTHR12406; PTHR12406; 1.
DR   Pfam; PF01734; Patatin; 1.
DR   SUPFAM; SSF52151; SSF52151; 1.
DR   PROSITE; PS51635; PNPLA; 1.
PE   1: Evidence at protein level;
KW   Acyltransferase; Alternative splicing; Complete proteome;
KW   Disease mutation; Glycoprotein; Hydrolase; Lipid degradation;
KW   Lipid metabolism; Membrane; Obesity; Polymorphism; Reference proteome;
KW   Signal-anchor; Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    481       Patatin-like phospholipase domain-
FT                                containing protein 3.
FT                                /FTId=PRO_0000064458.
FT   TOPO_DOM      1     41       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     42     62       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     63    481       Lumenal. {ECO:0000255}.
FT   DOMAIN       10    179       PNPLA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF        14     19       GXGXXG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF        45     49       GXSXG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF       166    168       DGA/G. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   ACT_SITE     47     47       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   ACT_SITE    166    166       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   CARBOHYD     89     89       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    280    280       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ      59     62       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036222.
FT   VARIANT      76     76       A -> T (in NAFLD1; unknown pathological
FT                                significance; dbSNP:rs746140741).
FT                                {ECO:0000269|PubMed:27288299}.
FT                                /FTId=VAR_077543.
FT   VARIANT      99     99       C -> G (in dbSNP:rs2076213).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_015845.
FT   VARIANT     104    104       A -> V (in NAFLD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27288299}.
FT                                /FTId=VAR_077544.
FT   VARIANT     115    115       G -> C (in dbSNP:rs2076212).
FT                                {ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_015846.
FT   VARIANT     148    148       I -> M (common polymorphism; fails to
FT                                hydrolyze emulsified triglycerides;
FT                                associated with increased hepatic fat
FT                                content and serum aspartate
FT                                aminotransferase concentrations;
FT                                dbSNP:rs738409).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18728122,
FT                                ECO:0000269|PubMed:18820647,
FT                                ECO:0000269|PubMed:19224197,
FT                                ECO:0000269|PubMed:19738004,
FT                                ECO:0000269|PubMed:20034933}.
FT                                /FTId=VAR_019961.
FT   VARIANT     200    200       T -> M (in NAFLD1; unknown pathological
FT                                significance; dbSNP:rs190477302).
FT                                {ECO:0000269|PubMed:27288299}.
FT                                /FTId=VAR_077545.
FT   VARIANT     216    216       T -> P (in dbSNP:rs35726887).
FT                                /FTId=VAR_053814.
FT   VARIANT     434    434       K -> E (in dbSNP:rs2294918).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15461802,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_015847.
FT   VARIANT     453    453       S -> I (common polymorphism; associated
FT                                with lower hepatic fat content in African
FT                                Americans; dbSNP:rs6006460).
FT                                {ECO:0000269|PubMed:18820647}.
FT                                /FTId=VAR_053815.
SQ   SEQUENCE   481 AA;  52865 MW;  1ED0341B5AF5B6CB CRC64;
     MYDAERGWSL SFAGCGFLGF YHVGATRCLS EHAPHLLRDA RMLFGASAGA LHCVGVLSGI
     PLEQTLQVLS DLVRKARSRN IGIFHPSFNL SKFLRQGLCK CLPANVHQLI SGKIGISLTR
     VSDGENVLVS DFRSKDEVVD ALVCSCFIPF YSGLIPPSFR GVRYVDGGVS DNVPFIDAKT
     TITVSPFYGE YDICPKVKST NFLHVDITKL SLRLCTGNLY LLSRAFVPPD LKVLGEICLR
     GYLDAFRFLE EKGICNRPQP GLKSSSEGMD PEVAMPSWAN MSLDSSPESA ALAVRLEGDE
     LLDHLRLSIL PWDESILDTL SPRLATALSE EMKDKGGYMS KICNLLPIRI MSYVMLPCTL
     PVESAIAIVQ RLVTWLPDMP DDVLWLQWVT SQVFTRVLMC LLPASRSQMP VSSQQASPCT
     PEQDWPCWTP CSPKGCPAET KAEATPRSIL RSSLNFFLGN KVPAGAEGLS TFPSFSLEKS
     L
//
